Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02026622
Other study ID # PHAO 2012 - TD / EMPHILINE
Secondary ID
Status Completed
Phase N/A
First received October 29, 2013
Last updated August 31, 2015
Start date February 2013
Est. completion date August 2015

Study information

Verified date August 2015
Source University Hospital, Tours
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

The main objective is to compare the physiological reactivity (heart and respiratory rates, galvanic skin response, cerebral perfusion, and startle) in the three phases of emotion between depressive subjects, subjects remitted from depression and control subjects.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date August 2015
Est. primary completion date May 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Female between 18 and 55

- Informed consent form signed

- Affiliated to a medical insurance

- visual and hearing abilities suitable for exams

- for the depressive group (group D): major depressive disorder according to the DSM-IV criteria as evaluated by the MINI test and MADRS score =22

- for the depressive patients in remission's group (group R) : matched on age, at least 1 history of major depressive disorder in the last 10 years and solved for more than 6 months, and MADRS score < 9

- for the control subjects (group T) : matched on age, no psychiatric history, MADRS score < 9

Exclusion Criteria:

- psychotic disorder, bipolar disorder, addiction, suspected dementia (MMSE<25)

- current betablockers or neuroleptics treatment

- any current organic unstable pathology

- history of serious cardiovascular disease (coronary syndrome, cardiac arrythmia, etc.)

- smoking > 10 PY

- history of serious neurologic disease (stroke, cerebral tumour, serious cranial trauma, headache, ...)

- contra-indication to MRI

- uncorrected vision or audition troubles

- patient under juridic protection

- pregnancy, lactating or female without reliable contraception

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Intervention

Behavioral:
psychometric tests
NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
Device:
MRI
ASL, rest f-MRI, FLAIR, white matter hyper intensities load
transcranial doppler and TPI
transcranial doppler TPI
Behavioral:
explicitative interview


Locations

Country Name City State
France University Hospital of Tours Tours

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Tours

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary amplitude variations of heart and respiratory rate, cerebral pulsatility, galvanic skin response and startle as measure of physiological reactivity amplitude variations of heart and respiratory rate, cerebral pulsatility, galvanic skin response and startle. one day No
Secondary MRI data as measure of cerebral perfusion, volume of leukoaraiosis and default network (fMRI at rest) cerebral perfusion measured by MRI (Arterial Spin Labelling) volume of leukoaraiosis default network (fMRI at rest) one day No
Secondary ultrasound data of doppler as measure of cerebral pulstility doppler index of middle cerebral artery At the same time, heart rate variability and cerebral pulsatility at rest will be collected one day No
Secondary score of psychometric tests as measure of emotional state MADRS score, ERD score, STAI-E score, anhedonia score, Neo-PI score, and the subjective assessment of emotional arousal (self Manikin assessment). one day No
Secondary spontaneous verbal production to emotional pictures and explicitative interviews spontaneous verbal production to emotional pictures and explicitative interviews one day No
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A